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Excessive collagen turnover 
products are released during 
colorectal cancer progression and 
elevated in serum from metastatic 
colorectal cancer patients
S. N. Kehlet1,2, R. Sanz-Pamplona3, S. Brix2, D. J. Leeming1, M. A. Karsdal1 & V. Moreno3,4
During cancer progression, the homeostasis of the extracellular matrix becomes imbalanced with 
an excessive collagen remodeling by matrix metalloproteinases. As a consequence, small protein 
fragments of degraded collagens are released into the circulation. We have investigated the potential 
of protein fragments of collagen type I, III and IV as novel biomarkers for colorectal cancer. Specific 
fragments of degraded type I, III and IV collagen (C1M, C3M, C4M) and type III collagen formation  
(Pro-C3) were assessed in serum from colorectal cancer patients, subjects with adenomas and matched 
healthy controls using well-characterized and validated ELISAs. Serum levels of the biomarkers were 
significantly elevated in colorectal cancer patients compared to subjects with adenomas (C1M, Pro-C3, 
C3M) and controls (C1M, Pro-C3). When patients were stratified according to their tumour stage, all four 
biomarkers were able to differentiate stage IV metastatic patients from all other stages. Combination 
of all markers with age and gender in a logistic regression model discriminated between metastatic 
and non-metastatic patients with an AUROC of 0.80. The data suggest that the levels of these collagen 
remodeling biomarkers may be a measure of tumour activity and invasiveness and may provide new 
clinical tools for monitoring of patients with advanced stage colorectal cancer.
Colorectal cancer (CRC) is the third most common cancer and the fourth most common cause of cancer-related 
death worldwide, accounting for roughly 600.000 deaths per year1. The 5-year survival rate decreases drastically 
with advanced stages, being 90% for local tumours in initial stages and 12% in advanced stages with metastasis2. 
Clinical symptoms often appear at the late stages when the tumour has started to metastasize resulting in late 
diagnosis and lower survival rates3. CRC screening has resulted in a reduction in mortality4 but the optimal 
diagnostic test has not yet been found. The standard fecal occult blood test has a low sensitivity as not all tumours 
cause bleeding, giving rise to many false negatives. Colonoscopy, though it has a high sensitivity (92–99%) for 
both pre-malignant lesions and tumours, is invasive, inconvenient for the patients and associated with high-cost5, 
consequently inappropriate as screening tool to identify early stages of CRC. Thus alternative diagnostic tools 
have to be identified.
Serological biomarkers have the advantages of being easy to collect, non-invasive, typically low-cost, and have 
the ability to be followed over the course of the disease. Identification of serological biomarkers that can aid in 
early detection, diagnosis, disease monitoring and in individual treatment selection of CRC patients could have 
a high impact on the patient outcome.
The local microenvironment of a tumour has been shown to play important roles in tumour pathogenesis 
and there is much focus on the extracellular matrix (ECM) and its remodeling as contributor to malignancy6,7. 
The ECM is constantly being remodeled and in the healthy tissue there is a balanced ratio between degradation 
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and formation of ECM proteins. Disruption of this homeostasis may act as a driver of cancer development and 
invasion. Excessive ECM remodeling is characterized both by an increased collagen deposition (desmoplasia) and 
crosslinking leading to tissue stiffening as well as an increased expression of matrix metalloproteinases (MMPs)6,8. 
As a consequence, increased levels of tissue - and cancer-specific ECM turnover products, so-called neo-epitopes, 
are released into the circulation making them potential as novel blood-based biomarkers. Many of these proteins 
have been uniquely modified by the pathology, such as the generation of a unique degradation site by a cancer 
dependent protease (e.g. MMP) in a signature protein (e.g. collagen) providing a so-called protein fingerprint. 
This combination is more related to pathogenesis than unmodified proteins and therefore potential candidates 
for novel biomarkers in cancer9.
Neo-epitope biomarkers have been shown to have a diagnostic potential in lung cancer10, breast cancer11, 
ovarian cancer11 and pancreatic cancer12. In this study, we investigated whether serum biomarkers reflecting 
collagen remodeling could differentiate between colorectal cancer patients, subjects with adenomas and healthy 
controls. Furthermore, we examined if the individual biomarkers or combinations hereof could be used to stratify 
patients according to their tumour stage.
Results
Collagen remodeling biomarkers are elevated in colorectal cancer patients compared to sub-
jects with adenomas and healthy controls. Serum levels of biomarkers specifically reflecting type I 
(C1M), type III (C3M) and type IV (C4M) collagen degradation and type III collagen formation (Pro-C3) were 
measured in healthy controls, subjects with adenomas and colorectal cancer patients. The data are presented in 
Fig. 1. In detail, the level of C1M and Pro-C3 were significantly elevated in colorectal cancer patients compared 
to healthy controls (C1M: p < 0.001, Pro-C3: p < 0.0001) and subjects with adenomas (C1M: p < 0.0001, Pro-C3: 
p < 0.0001). C3M was significantly elevated in colorectal cancer patients compared to subjects with adenomas 
(p < 0.001). No significant difference was observed between the groups for C4M.
These data suggest that altered type I and type III collagen remodeling is ongoing in colorectal cancer and not 
in the healthy tissue and pre-malignant stages. This reflects that an altered collagen turnover and the release of 
collagen protein fragments to the circulation is a pathological feature of colorectal cancer.
Figure 1. Serum levels of MMP-mediated degradation of type I collagen (C1M), type III collagen (C3M) 
and type IV collagen (C4M) and formation of type III collagen (Pro-C3). Groups were compared using a 
Kruskal–Wallis test. The p-values were adjusted to account for multiple comparisons using Dunnett’s method. 
Significance levels: * * p < 0.01, * * * p < 0.001 and * * * * p < 0.0001.
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Collagen remodeling biomarkers are elevated in stage IV colorectal cancer patients. To inves-
tigate if the collagen remodeling biomarkers could be used to stratify patients according to their tumour stage, 
we divided the colorectal cancer patients into four groups according to their tumour stage, excluding the three 
patients with carcinoma in situ (Table 1). The data are presented in Fig. 2. All four biomarkers were significantly 
elevated in patients with stage IV tumours compared to all other stages (p < 0.05 to < 0.0001, dependent on the 
marker). No differences were observed among patients diagnosed with stage I-III. The high level of all markers in 
stage IV patients indicates that collagen remodeling takes part in colorectal cancer progression and invasion and 
that these four biomarkers are a measure of tumour activity in advanced stages.
Discriminative power of collagen remodeling biomarkers for metastatic and non-metastatic 


















Healthy controls 99 64.6 60.1 ± 6.3 – – – – –
Adenomas 99 26.3 59.8 ± 5.9 – – – – –
Colorectal cancer cases 196 32.1 63.1 ± 10.4 3 39 47 80 27
Table 1.  Patients demographics and clinical profiles.
Figure 2. Serum levels of MMP-mediated degradation of type I collagen (C1M), type III collagen (C3M) 
and type IV collagen (C4M) and formation of type III collagen (Pro-C3) in colorectal cancer patients 
stratified according to their tumour stage. Groups were compared using a Kruskal–Wallis test. The p-values 
were adjusted to account for multiple comparisons using Dunnett´s method. Significance levels: * p < 0.05,  
* * p < 0.01, * * * p < 0.001 and * * * * p < 0.0001.
www.nature.com/scientificreports/
4Scientific RepoRts | 6:30599 | DOI: 10.1038/srep30599
was used to evaluate the discriminative power of the four biomarkers for metastatic and non-metastatic colorectal 
cancer (Table 2). As shown in Table 2, Pro-C3 and C3M displayed the highest diagnostic accuracy in relation to 
identify metastatic tumours from non-metastatic tumours with an AUROC of 0.79 and 0.78, respectively. For 
each biomarker, the optimal cut-off value was determined by ROC curve analyses and the sensitivity and speci-
ficity are shown in Table 2.
We performed logistic regression analyses to calculate the best diagnostic value by combining all biomarkers 
and to correct for confounding factors (age and gender). Tumour stage (non-metastatic vs metastatic (stage IV)) 
was included as dependent variable and the four biomarkers, age and gender as explanatory variables. In this 
logistic regression model, C3M and Pro-C3 were found to be statistically significant (C3M: p = 0.006, Pro-C3: 
p = 0.002) and the diagnostic value for separating metastatic patients from non-metastatic patients increased to 
an AUROC of 0.80 (95% CI: 0.65–0.91), a sensitivity of 92.6% and a specificity of 67.3% when 0.097 was used as 
cut-off value. Based on the logistic regression model, we propose the following algorithm which could be used as 
an aid for clinicians to manage patients that have been diagnosed with colorectal cancer and to assess the severity 
and tumour progression/activity by collecting a blood sample and measure Pro-C3 and C3M concentrations in 
serum: Tumour activity score = − 4.96 + 0.16 × C3M + 0.07 × Pro-C3. Applying this model to the data from the 
current study, an AUC of 0.83 is achieved for detecting advanced stage colorectal cancer patients. This model/
algorithm needs to be further validated in large clinical studies in order to identify the appropriate score for 
advanced stage colorectal cancer.
Discussion
In the present study we measured a panel of four collagen remodeling biomarkers in serum from patients with 
colorectal cancer, subjects with adenomas and healthy controls. To our knowledge, this is the first study investi-
gating the diagnostic potential of type I, III and IV collagen turnover biomarkers in colorectal cancer. The main 
finding was that type I, III and IV collagen remodeling biomarkers were significantly elevated in stage IV meta-
static colorectal cancer compared to all other stages. Combination of all four biomarkers resulted in differentia-
tion between metastatic and non-metastatic patients with an AUROC of 0.80, while Pro-C3 alone gave rise to an 
AUROC of 0.79. Together, the data demonstrate that these biomarkers, especially Pro-C3, can be used to assess 
tumour activity/invasiveness in patients diagnosed with colorectal cancer based on a blood sample. Moreover, the 
data indicate that the excessive collagen degradation (C1M, C3M and C4M) and formation (Pro-C3) observed 
in metastatic colorectal cancer patients could play a role in cancer pathogenesis, either as a driver of tumour pro-
gression or by being a consequence hereof.
Elevated levels of collagen-derived fragments have been detected in other cancer types, including lung-10, 
breast-11, ovary-11 and pancreatic cancer12. Our results together with these data support that ECM remodeling is 
an important part of and/or contributes to cancer development and progression6,7. In fact, it is becoming widely 
accepted that ECM remodeling and dysregulation directly affect the hallmarks of cancer as defined by Hanahan 
and Weinberg in 200013–15.
C1M and C3M reflects interstitial matrix remodeling, where the C1M assay measures a type I collagen degra-
dation fragment generated by cleavage with MMP-2, − 9 and − 1316 and the C3M assay measures a type III colla-
gen degradation fragment generated by cleavage with MMP-917, respectively. C4M reflects basement membrane 
remodeling and measures a type IV collagen α 1- chain fragment generated by cleavage with MMP-1218. These 
four MMPs (2, 9, 12 and 13) have in fact been associated with colorectal cancer supporting an increased collagen 
degradation19–21. The disruption of the basement membrane and the interstitial matrix is an essential prerequisite 
for tumour invasion. For tumour cells to metastasize, they must not only degrade the matrices of the colon wall, 
but also the matrices of lymphatic system, blood vessels and at the secondary site. Degradation of the interstitial 
matrix paves the way for the tumour cells thereby enhancing migration across the matrix to nearby lymph nodes 
and blood vessels19,22. In the current study, C1M, C3M and C4M were significantly elevated in stage IV patients. 
In theory, we would expect the basement membrane and interstitial matrix of the colon wall to be degraded at 
early stages of invasion (stage I-III), however this was not detectable in serum by the current biomarker assays. 
This may be explained by a lower MMP activity at earlier tumour stages or perhaps by increased cellular uptake 
of collagen fragments in initial stages. Our results might rely on an ongoing degradation of both the basement 
membrane and interstitial matrix of the colon wall leading to tumour progression into deeper tissues and exces-
sive release of collagen turnover products into the circulation as a consequence of metastasis. At this stage, the 
basement membrane and interstitial matrix of the lymphatic system, blood vessels and the secondary site might 
also have been breached, likewise resulting in enhanced levels of collagen fragments detectable in serum.
Pro-C3 measures the true formation of type III collagen as the antibody is directed against the cleavage site 
of the N-terminal collagen III pro-peptide23 which are released during collagen formation and maturation. This 
marker has been extensively studied in liver fibrosis as a biomarker of progression and burden of disease24–27. Cox 
Biomarker Cut-off value (ng/mL) Sensitivity Specificity AUROC (95% CI) p-value
C1M 30.7 77.8 67.9 0.74 (0.62–0.87) < 0.0001
C3M 11.9 85.7 65.5 0.78 (0.66–0.89) < 0.0001
C4M 52.3 96.4 43.0 0.74 (0.61–0.87) < 0.0001
Pro-C3 10.4 88.9 66.1 0.79 (0.65–0.91) < 0.0001
Table 2.  Discriminative performance of collagen remodeling biomarkers for detecting metastatic 
colorectal cancer (stage IV) versus non-metastatic (stage I–III).
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and Erler28 have recently reviewed the link between fibrosis and tumour metastasis. It was discussed that tumour 
cells can prepare a pre-metastatic niche in a manner that resembles the development of fibrosis. In order to con-
vert an unfavorable tumour environment of a distant site into favorable surroundings, tumour cells secrete a lot 
of factors before and upon arrival at the metastatic niche. This includes factors that promote increased collagen 
deposition and crosslinking as observed in fibrotic tissue. The increased formation of type III collagen measured 
in stage IV patients may originate from the metastatic niche either as a result of tissue priming or upon tumour 
cell arrival. This is in line with several studies showing the importance of increased collagen deposition in the 
metastatic niche for further tumour progression29–32.
Identification of neo-epitope biomarkers that directly reflect the changes of the extracellular matrix during 
cancer could be a new way handling the medical need in colorectal cancer. Each neo-epitope results from a 
specific pathological process giving rise to a very unique and specific biomarker9. The fact that the biomarkers 
were significantly elevated in stage IV patients and had a high discriminative value for metastatic patients, clearly 
indicates that the level of collagen remodeling biomarkers is a measure of tumour activity and severity. Therefore, 
it is likely that these biomarkers could be novel candidates as tools to monitor colorectal cancer patients with 
advanced stages. Such tools would be valuable since it is often the metastases rather than the primary tumour 
which cause the poor prognosis of cancer patients33. Blocking the invasion of cancer and its growth at the dis-
tant site could therefore improve the patient outcome. The ECM is in fact an emerging target for cancer drug 
therapy34–36. Several preclinical studies have investigated key ECM proteins as targets for novel cancer drugs 
(reviewed in ref. 34). The present biomarkers have a potential as treatment of efficacy biomarkers in relation to 
ECM modifying drugs. Since the four biomarkers investigated here reflect excessive ECM remodeling, they might 
be able to identify patients with a densely remodeled stroma who would benefit most from ECM targeting drugs. 
Furthermore, the biomarkers could be used to monitoring advanced stage patients after therapy, as we hypothe-
size that circulating levels would decrease after successful treatment of the tumour creating a homeostatic tissue 
environment and then increase again if there is recurrence. Carcinoembryonic antigen (CEA) is the most widely 
used serum biomarker in patients with colorectal cancer37. The poor sensitivity of this test for early stage tumours 
makes it unsuitable for screening and early detection and the main use of CEA in colorectal cancer is for surveil-
lance and monitoring before and after surgery/treatment. However the usefulness of CEA is controversial37–39. 
CEA is an oncofetal antigen whereas the investigated biomarkers are designed as a measure of tumour activity, 
invasiveness and pathology specific which may increase specificity and sensitivity. However, this has to be vali-
dated in larger cohorts together with CEA measurements.
One limitation of this study is its cross-sectional nature. To fully elucidate the prognostic applicability and 
treatment efficacy of the collagen turnover biomarkers, larger longitudinal studies are needed. Another limitation 
is the absence of a replication/validation cohort which would have supported the findings. However, we find these 
preliminary results to be important steps towards identifying novel blood-based biomarker tools in colorectal 
cancer.
In conclusion, colorectal cancer is a field with an urgent need for biomarkers that can aid in diagnosis and 
prognosis. We have assessed a panel of biomarkers reflecting collagen turnover of the extracellular matrix in 
patients with colorectal cancer, subjects with adenomas and controls. All markers were significantly elevated in 
stage IV patients suggesting that excessive collagen turnover takes part in cancer progression and metastasis. As 
these markers are designed to measure tumour activity, they may increase the understanding of cancer pathology 
and, if validated in larger clinical studies, provide new clinical tools for patient monitoring and efficacy of 
treatment.
Methods
Patient samples. This study included serum samples from 394 individuals comprising 99 healthy controls, 
99 patients with adenomas and 196 patients with colorectal cancer at different stages. For all individuals, 9 ml of 
blood was collected and centrifuged to separate serum. Then, samples were divided into single-use aliquots and 
preserved at − 80 °C. All controls and patients were recruited at the Bellvitge University Hospital (Barcelona, 
Spain) and all samples were handled the exact same way. Written informed consent was obtained from all patients 
and the Ethics Committee of the Bellvitge University Hospital approved the protocol with reference PR073/11. 
The study was carried out in accordance with ICH-GCP and according to the Declaration of Helsinki. Table 1 
shows the detailed characteristics of healthy controls, adenomas and colorectal cancer patients.
Protein Fingerprint biomarker analysis. The Protein Fingerprint biomarkers of matrix metalloprotein-
ase (MMP) degraded type I, type III and type IV collagen (C1M, C3M, C4M) and type III collagen formation 
(Pro-C3) were assessed in serum as previously described16–18,23. Briefly, 96-well pre-coated streptavidin plates 
were coated with biotinylated synthetic peptides specific for the protein of interest and incubated for 30 minutes 
at 20 °C. 20 μ L of standard peptide or pre-diluted serum sample were added to designated wells followed by the 
addition of peroxidase-conjugated specific monoclonal antibodies and incubated for 1 h at 20 °C or overnight at 
4 °C. Finally, tetramethylbenzinidine (TMB) (cat. 438OH, Kem-En-Tec Diagnostics, Denmark) was added to each 
well and the plates were incubated for 15 minutes at 20 °C. All incubation steps included shaking at 300 rpm and 
after each incubation step, the plates were washed five times with wash buffer (20 mM Tris, 50 mM NaCl, pH 7.2). 
The enzymatic reaction was stopped by adding 0.18 M H2SO4 and absorbance was measured at 450 nm with 
650 nm as reference. A calibration curve was plotted using a 4-parameter logistic curve fit.
Statistical analysis. The levels of the individual biomarkers in serum samples in each group (controls, ade-
nomas and cases) were compared using a Kruskal–Wallis test (non-parametric test). The p-values were adjusted 
to account for multiple comparisons using Dunnett´s method.
www.nature.com/scientificreports/
6Scientific RepoRts | 6:30599 | DOI: 10.1038/srep30599
The diagnostic power of individual and combined markers was investigated by the area under the receiver 
operating characteristics (AUROC). Sensitivity and specificity were determined for appropriate cut-off values 
based on the ROC curves. Logistic regression analyses were carried out to calculate the best diagnostic value 
when combining all biomarkers and correcting for age and gender. To correct for over fitting, an internal valida-
tion was conducted by calculating the bootstrap optimism-corrected AUC (the data were resampled 1000 times 
with the bootstrapping method).
Unless otherwise stated, data are shown as Tukey box plots, where the boxes represent the 25th, 50th and 
75th percentiles. The whiskers represent the lowest and highest value, except outliers, which are higher than 1.5 
times the 75th percentile or lower than 1.5 times the 25th percentile. P-values < 0.05 were considered significant. 
Statistical analyses were performed using the R statistical computing software (http://www.r-project.org), 
MedCalc Statistical Software version 12 (MedCalc Software, Ostend, Belgium) and GraphPad Prism version 
6 (GraphPad Software, Inc., CA, USA). Graphs were designed using GraphPad Prism version 6 (GraphPad 
Software, Inc., CA, USA).
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